Company / SG&A Expense
Adaptimmune Therapeutics PLC SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$87.3M
FY2024
5-year range
$45.8M / $87.3M
FY2020-FY2024
Trend
+18.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 5 consecutive years, from $43M in FY2019 to $87M in FY2024.
Based on SEC 10-K filings.
$87M in FY2024 with a 5-year CAGR of +15.0%.
Increased from $63M to $87M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.0%
- 5-Year CAGR
- +15.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Adaptimmune Therapeutics PLC's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +15.0%, indicating consistent growth.
- In FY2024, sg&a expense increased 18.7% year-over-year.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $87.3M | +18.7% |
| FY2023 | $73.5M | +16.0% |
| FY2022 | $63.4M | +10.6% |
| FY2021 | $57.3M | +25.1% |
| FY2020 | $45.8M | +5.5% |
| FY2019 | $43.4M | -0.5% |
| FY2018 | $43.6M | +40.2% |
| FY2017 | $31.1M | +34.0% |
| FY2016 | $23.2M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026